Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  alpelisib
Find trials that include:  Any drugs shown
Results 1-17 of 17 for your search:
Start Over
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719X2104, NCI-2013-00766, 2011-006017-34, NCT01602315
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2103, NCI-2013-02457, 2012-002138-35, NCT01719380
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLJM716X2103, NCI-2013-01355, NCT01822613
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, NCT01872260
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGH447X2103C, NCI-2014-01682, 2013-004959-21, NCT02144038
PI3K Inhibitor BYL719 and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER-2 Negative Stage III or IV Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719XUS06T, NCI-2015-00802, STUDY00001632, NCT02379247
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
BYL719 and Letrozole With or Without Trastuzumab in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 12101, NCI-2013-00102, CBYL719XUS03T, SU2C B07, NCT01791478
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CBGJ398X2102, NCI-2013-01763, NCT01928459
PI3K Inhibitor BYL719 and Trastuzumab Emtansine in Treating Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab or Chemotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 13B06, NCI-2013-02224, STU00087202, NCT02038010
LJM716, BYL719, and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-057, NCI-2014-01362, NCT02167854
Sotrastaurin Acetate and PI3K Inhibitor BYL719 in Treating Patients with Metastatic Uveal Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAN4901, NCI-2015-00753, CAEB071AUS01T, NCT02273219
Cetuximab, BYL719, and Intensity-Modulated Radiation Therapy in Treating Patients with Stage III-IVB Head and Neck Squamous Cell Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-116, NCI-2014-02290, NCT02282371
Start Over